Squarepoint

Squarepoint’s Decoy Therapeutics DCOY Stock Holding History

Squarepoint’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3	Closed	-$93K	–	3566
2020 Q4	$93K	Buy	+3	New	+$87.9K	﹤0.01%	2734
2020 Q3	–	Hold	0	–	–	–	2429

Other funds holding DCOY

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Squarepoint's DCOY Position: Q1 2021 in Review

Squarepoint sold out of Decoy Therapeutics (DCOY) in Q1 2021, closing a stake of 3 shares — an estimated $93K sold.

Squarepoint first reported a position in DCOY in Q4 2020 and held it in 1 quarter. The position peaked at $93K in Q4 2020. 23 funds tracked by Wall St. Rank hold DCOY as of Q1 2021.

Squarepoint reported no remaining Decoy Therapeutics position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 3 Decoy Therapeutics shares in Q1 2021, an estimated $93K.
Squarepoint first reported a position in Decoy Therapeutics in Q4 2020 and held it in 1 quarter.
Squarepoint's Decoy Therapeutics position peaked at $93K in Q4 2020.
23 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.